{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:04:36Z","timestamp":1792497876701,"version":"4.5.0"},"reference-count":144,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Inflammatory processes are essential for innate immunity and contribute to carcinogenesis in various malignancies, such as colorectal cancer, esophageal cancer and lung cancer. Pharmacotherapies targeting inflammation have the potential to reduce the risk of carcinogenesis and improve therapeutic efficacy of existing anti-cancer treatment. Non-steroidal anti-inflammatory drugs (NSAIDs), comprising a variety of structurally different chemicals that can inhibit cyclooxygenase (COX) enzymes and other COX-independent pathways, are originally used to treat inflammatory diseases, but their preventive and therapeutic potential for cancers have also attracted researchers\u2019 attention. Pharmacogenomic variability, including distinct genetic characteristics among different patients, can significantly affect pharmacokinetics and effectiveness of NSAIDs, which might determine the preventive or therapeutic success for cancer patients. Hence, a more comprehensive understanding in pharmacogenomic characteristics of NSAIDs and cancer-related inflammation would provide new insights into this appealing strategy. In this review, the up-to-date advances in clinical and experimental researches targeting cancer-related inflammation with NSAIDs are presented, and the potential of pharmacogenomics are discussed as well.<\/jats:p>","DOI":"10.3389\/fphar.2022.1078766","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T01:06:06Z","timestamp":1670202366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics"],"prefix":"10.3389","volume":"13","author":[{"given":"Hongjin","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senyi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.1158\/0008-5472.Can-08-1060","article-title":"Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo","volume":"68","author":"Ahmadi","year":"2008","journal-title":"Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/j.1349-7006.2009.01322.x","article-title":"Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis","volume":"100","author":"Amano","year":"2009","journal-title":"Cancer Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/gcc.22157","article-title":"The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: Haplotype associations and gene\u2013environment interactions","volume":"53","author":"Angstadt","year":"2014","journal-title":"Genes Chromosom. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.tips.2012.02.004","article-title":"Prostaglandins and chronic inflammation","volume":"33","author":"Aoki","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"27613","DOI":"10.1074\/jbc.M201119200","article-title":"Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line","volume":"277","author":"Arico","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"47762","DOI":"10.1074\/jbc.M307265200","article-title":"Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer","volume":"278","author":"Babbar","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B7","first-page":"3566","article-title":"CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk","volume":"61","author":"Bigler","year":"2001","journal-title":"Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/ijms18071522","article-title":"Pharmacogenomics of targeted agents for personalization of colorectal cancer treatment","volume":"18","author":"Bignucolo","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.annonc.2020.02.012","article-title":"Aspirin and the risk of colorectal and other digestive tract cancers: An updated meta-analysis through 2019","volume":"31","author":"Bosetti","year":"2020","journal-title":"Ann. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"9380","DOI":"10.1158\/0008-5472.Can-07-0710","article-title":"Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer","volume":"67","author":"Buchanan","year":"2007","journal-title":"Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1053\/j.gastro.2016.07.030","article-title":"Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes","volume":"151","author":"Cao","year":"2016","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.hpb.2020.09.024","article-title":"Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib","volume":"23","author":"Casadei-Gardini","year":"2021","journal-title":"HPB Oxf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/j.gastro.2007.09.035","article-title":"Aspirin dose and duration of use and risk of colorectal cancer in men","volume":"134","author":"Chan","year":"2008","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/jnci\/dji066","article-title":"Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma","volume":"97","author":"Chan","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"B15","doi-asserted-by":"publisher","first-page":"21272127","DOI":"10.1053\/j.gastro.2009.02.045","article-title":"Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma","volume":"136","author":"Chan","year":"2009","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1055-9965.Epi-08-1130","article-title":"Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma","volume":"18","author":"Chang","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1073\/pnas.2535911100","article-title":"Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression","volume":"101","author":"Chang","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B18","doi-asserted-by":"publisher","first-page":"102426","DOI":"10.1016\/j.redox.2022.102426","article-title":"Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR\/SREBP-1\/SCD1-mediated lipogenesis in PIK3CA-mutatnt colorectal cancer","volume":"55","author":"Chen","year":"2022","journal-title":"Redox Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.7150\/thno.24284","article-title":"Aspirin cooperates with p300 to activate the acetylation of H3K9 and promote FasL-mediated apoptosis of cancer stem-like cells in colorectal cancer","volume":"8","author":"Chen","year":"2018","journal-title":"Theranostics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrclinonc.2012.137","article-title":"Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms","volume":"9","author":"Chia","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1200\/jco.2011.41.0308","article-title":"Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy","volume":"30","author":"Choe","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7911","DOI":"10.1158\/0008-5472.Can-05-1288","article-title":"Tumor radiosensitization by antiinflammatory drugs: Evidence for a new mechanism involving the oxygen effect","volume":"65","author":"Crokart","year":"2005","journal-title":"Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","article-title":"Inflammation and cancer: Advances and new agents","volume":"12","author":"Crusz","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-021-00677-2","article-title":"CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression","volume":"6","author":"Cui","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1158\/0008-5472.Can-04-3814","article-title":"Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer","volume":"65","author":"Daikoku","year":"2005","journal-title":"Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"15041504","DOI":"10.1053\/j.gastro.2012.02.050","article-title":"Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells","volume":"142","author":"Din","year":"2012","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1200\/jco.2013.50.0322","article-title":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer","volume":"31","author":"Domingo","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"9962","DOI":"10.1074\/jbc.272.15.9962","article-title":"Inhibition of activator protein 1 activity and neoplastic transformation by aspirin","volume":"272","author":"Dong","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1200\/jco.2007.13.8081","article-title":"Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-cancer and leukemia group B trial 30203","volume":"26","author":"Edelman","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc3611","article-title":"Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms","volume":"13","author":"Elinav","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/jnci\/djq442","article-title":"Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial","volume":"102","author":"Elmets","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1158\/0008-5472.Can-16-1602","article-title":"IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment","volume":"77","author":"Fang","year":"2017","journal-title":"Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1182\/blood-2006-07-027458","article-title":"SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation\/activity and multiple myeloma cell growth","volume":"109","author":"Feng","year":"2007","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/bjc.2014.264","article-title":"Aspirin use and survival after the diagnosis of breast cancer: A population-based cohort study","volume":"111","author":"Fraser","year":"2014","journal-title":"Br. J. Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/bjc.2016.425","article-title":"Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study","volume":"116","author":"Frouws","year":"2017","journal-title":"Br. J. Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1002\/hep.30813","article-title":"Dose and duration of aspirin use to reduce incident hepatocellular carcinoma","volume":"70","author":"Fujiwara","year":"2019","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrd.2016.39","article-title":"Resolution of inflammation: A new therapeutic frontier","volume":"15","author":"Fullerton","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1126\/science.294.5548.1871","article-title":"Prostaglandins and leukotrienes: Advances in eicosanoid biology","volume":"294","author":"Funk","year":"2001","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/01.Jto.0000263712.61697.69","article-title":"Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)","volume":"2","author":"Gadgeel","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1158\/1078-0432.Ccr-13-2305","article-title":"COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis","volume":"20","author":"Gallouet","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10787-020-00765-9","article-title":"Pharmacodynamic mechanisms of anti-inflammatory drugs on the chemosensitization of multidrug-resistant cancers and the pharmacogenetics effectiveness","volume":"29","author":"Gholamian Dehkordi","year":"2021","journal-title":"Inflammopharmacology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clcc.2016.07.011","article-title":"The role of aspirin as antitumoral agent for heavily pretreated patients with metastatic colorectal cancer receiving capecitabine monotherapy","volume":"16","author":"Giampieri","year":"2017","journal-title":"Clin. Colorectal Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: Triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/s1470-2045(07)70146-8","article-title":"Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: The GEmcitabine-COxib in NSCLC (GECO) study","volume":"8","author":"Gridelli","year":"2007","journal-title":"Lancet. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1200\/jco.2016.70.7547","article-title":"Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status","volume":"35","author":"Hamada","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/1878-0261.12682","article-title":"Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction","volume":"14","author":"Han","year":"2020","journal-title":"Mol. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: A review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1126\/science.1215327","article-title":"The ancient drug salicylate directly activates AMP-activated protein kinase","volume":"336","author":"Hawley","year":"2012","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/s0092-8674(00)81664-5","article-title":"PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs","volume":"99","author":"He","year":"1999","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1158\/1078-0432.Ccr-07-4640","article-title":"Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer","volume":"14","author":"Holmes","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41571-020-00459-9","article-title":"Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age?","volume":"18","author":"Hou","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"Jco2101900","DOI":"10.1200\/jco.21.01900","article-title":"Modification of the association between frequent aspirin use and ovarian cancer risk: A meta-analysis using individual-level data from two ovarian cancer consortia","author":"Hurwitz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1200\/jco.2013.54.8875","article-title":"Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer","volume":"32","author":"Jacobs","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.trecan.2016.12.002","article-title":"Prostaglandin E2 signaling: Alternative target for glioblastoma?","volume":"3","author":"Jiang","year":"2017","journal-title":"Trends Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12943-020-01178-6","article-title":"Dying tumor cell-derived exosomal miR-194-5p potentiates survival and repopulation of tumor repopulating cells upon radiotherapy in pancreatic cancer","volume":"19","author":"Jiang","year":"2020","journal-title":"Mol. Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1042\/bj20020279","article-title":"The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: A plausible link with its anti-tumour effect and cardiovascular risks","volume":"366","author":"Johnson","year":"2002","journal-title":"Biochem. J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.bcp.2011.07.096","article-title":"Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: A novel cyclooxygenase-inhibition-independent effect","volume":"82","author":"Kato","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.1158\/0008-5472.Can-06-0325","article-title":"Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma","volume":"66","author":"Kern","year":"2006","journal-title":"Cancer Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1053\/j.gastro.2017.12.001","article-title":"Regular use of aspirin or non-aspirin nonsteroidal anti-inflammatory drugs is not associated with risk of incident pancreatic cancer in two large cohort studies","volume":"154","author":"Khalaf","year":"2018","journal-title":"Gastroenterology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1073\/pnas.0409721102","article-title":"The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis","volume":"102","author":"Kolluri","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1158\/0008-5472.can-03-2396","article-title":"3-phosphoinositide-dependent protein kinase-1\/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells","volume":"64","author":"Kulp","year":"2004","journal-title":"Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"101175","DOI":"10.1016\/j.redox.2019.101175","article-title":"15-Keto prostaglandin E(2) suppresses STAT3 signaling and inhibits breast cancer cell growth and progression","volume":"23","author":"Lee","year":"2019","journal-title":"Redox Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1158\/2159-8290.Cd-12-0101","article-title":"Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling","volume":"2","author":"Li","year":"2012","journal-title":"Cancer Discov."},{"key":"B66","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/0008-5472.Can-13-2245","article-title":"6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1","volume":"74","author":"Li","year":"2014","journal-title":"Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/gutjnl-2014-308260","article-title":"Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: A meta-analysis","volume":"64","author":"Li","year":"2015","journal-title":"Gut"},{"key":"B68","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1158\/1078-0432.Ccr-15-0198","article-title":"Aspirin suppresses the growth and metastasis of osteosarcoma through the NF-\u03baB pathway","volume":"21","author":"Liao","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/hep.31879","article-title":"Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort","volume":"74","author":"Liao","year":"2021","journal-title":"Hepatology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1158\/0008-5472.Can-06-3431","article-title":"Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon","volume":"67","author":"Liou","year":"2007","journal-title":"Cancer Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1074\/jbc.M202443200","article-title":"NS-398 and piroxicam suppress UVB-induced activator protein 1 activity by mechanisms independent of cyclooxygenase-2","volume":"278","author":"Liu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/JTO.0b013e3182542752","article-title":"Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer","volume":"7","author":"Liu","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.lungcan.2020.08.023","article-title":"Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer","volume":"149","author":"Liu","year":"2020","journal-title":"Lung Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e2032072","DOI":"10.1001\/jamanetworkopen.2020.32072","article-title":"Evaluation of aspirin use with cancer incidence and survival among older adults in the prostate, lung, colorectal, and ovarian cancer screening trial","volume":"4","author":"Loomans-Kropp","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B75","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.pcad.2016.02.001","article-title":"Which aspirin dose and preparation is best for the long-term prevention of cardiovascular disease and cancer? Evidence from a systematic review and network meta-analysis","volume":"58","author":"Lotrionte","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.canlet.2014.09.027","article-title":"Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK\/p38\/NF-\u03baB signal cascade","volume":"356","author":"Lu","year":"2015","journal-title":"Cancer Lett."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1172\/jci121985","article-title":"Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1\/thromboxane A2","volume":"129","author":"Lucotti","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/ajg.2009.758","article-title":"The safety and efficacy of celecoxib in children with familial adenomatous polyposis","volume":"105","author":"Lynch","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1158\/1078-0432.Ccr-20-3215","article-title":"Inflammation mediates the development of aggressive breast cancer following radiotherapy","volume":"27","author":"Ma","year":"","journal-title":"Clin. Cancer Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.clbc.2021.02.005","article-title":"Aspirin use and risk of breast cancer: A meta-analysis of observational studies from 1989 to 2019","volume":"21","author":"Ma","year":"","journal-title":"Clin. Breast Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1186\/s12885-015-1910-9","article-title":"Low-dose aspirin and survival from lung cancer: A population-based cohort study","volume":"15","author":"Mc Menamin \u00da","year":"2015","journal-title":"BMC Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/jnci\/djaa114","article-title":"Effect of aspirin on cancer incidence and mortality in older adults","volume":"113","author":"McNeil","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jama.2021.2454","article-title":"Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: The CALGB\/SWOG 80702 (alliance) randomized clinical trial","volume":"325","author":"Meyerhardt","year":"2021","journal-title":"Jama"},{"key":"B86","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/ijc.28381","article-title":"Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH\/HES1 and activating PPARG in colorectal cancer","volume":"134","author":"Moon","year":"2014","journal-title":"Int. J. Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jama.2015.1815","article-title":"Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants","volume":"313","author":"Nan","year":"2015","journal-title":"Jama"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/annonc\/mdq779","article-title":"Aspirin use and risk for lung cancer: A meta-analysis","volume":"22","author":"Oh","year":"2011","journal-title":"Ann. Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/path.4138","article-title":"Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL","volume":"229","author":"Pennarun","year":"2013","journal-title":"J. Pathol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.3390\/cancers14174134","article-title":"Reversing PD-1 resistance in B16F10 cells and recovering tumour immunity using a COX2 inhibitor","volume":"14","author":"Pi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B91","first-page":"63","article-title":"Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth","volume":"62","author":"Pradono","year":"2002","journal-title":"Cancer Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ygyno.2017.02.040","article-title":"A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology\/Gynecologic Oncology Group study","volume":"145","author":"Rader","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/jcph.1476","article-title":"Prolonged pharmacokinetic interaction between capecitabine and a CYP2C9 substrate, celecoxib","volume":"59","author":"Ram\u00edrez","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1158\/1078-0432.Ccr-06-0112","article-title":"A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer","volume":"12","author":"Reckamp","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/s0140-6736(19)31276-0","article-title":"Pharmacogenomics","volume":"394","author":"Roden","year":"2019","journal-title":"Lancet"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/0008-5472.Can-15-1360","article-title":"Aspirin suppresses the acquisition of chemoresistance in breast cancer by disrupting an nf?b-IL6 signaling Axis responsible for the generation of cancer stem cells","volume":"76","author":"Saha","year":"2016","journal-title":"Cancer Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1161\/atvbaha.113.301851","article-title":"Cathelicidin LL-37 induces angiogenesis via PGE2-EP3 signaling in endothelial cells, in vivo inhibition by aspirin","volume":"33","author":"Salvado","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cgh.2006.04.021","article-title":"Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention","volume":"4","author":"Samowitz","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"106379","DOI":"10.1016\/j.prostaglandins.2019.106379","article-title":"A journey of celecoxib from pain to cancer","volume":"147","author":"Saxena","year":"2020","journal-title":"Prostagl. Other Lipid Mediat."},{"key":"B100","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/gcc.22167","article-title":"Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: Colon cancer family registry","volume":"53","author":"Scherer","year":"2014","journal-title":"Genes Chromosom. Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/carcin\/bgs296","article-title":"I\u03baBK\u03b2 and NF\u03baB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry","volume":"34","author":"Seufert","year":"2013","journal-title":"Carcinogenesis"},{"key":"B103","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.1158\/0008-5472.Can-04-0206","article-title":"Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: Correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9","volume":"64","author":"Shishodia","year":"2004","journal-title":"Cancer Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of aspirin with hepatocellular carcinoma and liver-related mortality","volume":"382","author":"Simon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"E140","DOI":"10.1002\/mc.22058","article-title":"VEGFA, FLT1, KDR and colorectal cancer: Assessment of disease risk, tumor molecular phenotype, and survival","volume":"53","author":"Slattery","year":"2014","journal-title":"Mol. Carcinog."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/jnci\/djy017","article-title":"Effects of celecoxib and low-dose aspirin on outcomes in adjuvant aromatase inhibitor-treated patients: Cctg MA.27","volume":"110","author":"Strasser-Weippl","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"B107","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.canlet.2017.06.029","article-title":"Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition","volume":"406","author":"Sun","year":"2017","journal-title":"Cancer Lett."},{"key":"B108","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.actbio.2022.06.026","article-title":"Salicylic acid-based hypoxia-responsive chemodynamic nanomedicines boost antitumor immunotherapy by modulating immunosuppressive tumor microenvironment","volume":"148","author":"Sun","year":"2022","journal-title":"Acta Biomater."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1016\/j.ymthe.2018.08.002","article-title":"Disruption of chromosomal architecture of cox2 locus sensitizes lung cancer cells to radiotherapy","volume":"26","author":"Sun","year":"2018","journal-title":"Mol. Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/1078-0432.Ccr-05-1834","article-title":"Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer","volume":"12","author":"Sweeney","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"9247","DOI":"10.1038\/sj.onc.1208169","article-title":"Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation","volume":"23","author":"Takada","year":"2004","journal-title":"Oncogene"},{"key":"B112","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B113","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1158\/1078-0432.Ccr-21-0732","article-title":"Sulindac, a nonselective NSAID, reduces breast density in postmenopausal women with breast cancer treated with aromatase inhibitors","volume":"27","author":"Thompson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1158\/1535-7163.Mct-09-0758","article-title":"Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G","volume":"8","author":"Tinsley","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/1940-6207.Capr-10-0030","article-title":"Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition","volume":"3","author":"Tinsley","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1053\/j.gastro.2011.01.057","article-title":"Intestinal inflammation and cancer","volume":"140","author":"Ullman","year":"2011","journal-title":"Gastroenterology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrc1801","article-title":"Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics","volume":"6","author":"Ulrich","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1200\/jco.2011.34.6346","article-title":"Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: Results from the prospective vitamins and lifestyle (VITAL) study","volume":"29","author":"Walter","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","article-title":"Metabolism pathways of arachidonic acids: Mechanisms and potential therapeutic targets","volume":"6","author":"Wang","year":"","journal-title":"Signal Transduct. Target. Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1053\/j.gastro.2021.09.059","article-title":"Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal cancer","volume":"161","author":"Wang","year":"","journal-title":"Gastroenterology"},{"key":"B121","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/gut.2004.047100","article-title":"Prostaglandins and cancer","volume":"55","author":"Wang","year":"2006","journal-title":"Gut"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1884e1884","DOI":"10.1053\/j.gastro.2015.07.064","article-title":"Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice","volume":"149","author":"Wang","year":"2015","journal-title":"Gastroenterology"},{"key":"B124","doi-asserted-by":"publisher","first-page":"690219","DOI":"10.3389\/fonc.2021.690219","article-title":"Aspirin use and common cancer risk: A meta-analysis of cohort studies and randomized controlled trials","volume":"11","author":"Wang","year":"","journal-title":"Front. Oncol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1002\/cncr.32364","article-title":"Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study","volume":"125","author":"Wang","year":"2019","journal-title":"Cancer"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/mcg.0000000000001693","article-title":"Aspirin use and the risk of hepatocellular carcinoma: A meta-analysis","volume":"56","author":"Wang","year":"2022","journal-title":"J. Clin. Gastroenterol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"461","DOI":"10.21037\/atm.2020.03.125","article-title":"Aspirin use and endometrial cancer risk: A meta-analysis and systematic review","volume":"8","author":"Wang","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/0008-5472.can-03-1945","article-title":"Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity","volume":"64","author":"Wei","year":"2004","journal-title":"Cancer Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/jnr.23169","article-title":"Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: Relevant similarities to and important differences from celecoxib","volume":"91","author":"White","year":"2013","journal-title":"J. Neurosci. Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1124\/mol.62.5.1207","article-title":"Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth","volume":"62","author":"Wick","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.7150\/thno.35766","article-title":"Prostaglandin E(2) induces DNA hypermethylation in gastric cancer in vitro and in vivo","volume":"9","author":"Wong","year":"2019","journal-title":"Theranostics"},{"key":"B132","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nm.2608","article-title":"Prostaglandin E2 promotes intestinal tumor growth via DNA methylation","volume":"18","author":"Xia","year":"2012","journal-title":"Nat. Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"242ra84","DOI":"10.1126\/scitranslmed.3008455","article-title":"COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models","volume":"6","author":"Xu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40780-021-00209-8","article-title":"Effects of polymorphic cytochrome P450 2A6 genotypes on chemoprevention against colorectal tumors in single Japanese cohort using daily low-dose aspirin: Insights into future personalized treatments","volume":"7","author":"Yamazaki","year":"2021","journal-title":"J. Pharm. Health Care Sci."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/ijc.24862","article-title":"Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion","volume":"126","author":"Yanaoka","year":"2010","journal-title":"Int. J. Cancer"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1158\/1078-0432.Ccr-11-0934","article-title":"Molecular pathways: Pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus","volume":"18","author":"Yang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B137","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s13287-020-01884-4","article-title":"Aspirin mediates histone methylation that inhibits inflammation-related stemness gene expression to diminish cancer stemness via COX-independent manner","volume":"11","author":"Zhang","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1957605","DOI":"10.1080\/2162402x.2021.1957605","article-title":"The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2021","journal-title":"Oncoimmunology"},{"key":"B139","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1182\/blood-2011-04-350587","article-title":"PGE2 promotes angiogenesis through EP4 and PKA C\u03b3 pathway","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.3390\/cells11162505","article-title":"Adding cyclooxygenase inhibitors to immune checkpoint inhibitors did not improve outcomes in metastatic renal cell carcinoma","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"B141","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: Signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"B142","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: A systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"Jama"},{"key":"B143","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ccr.2010.04.023","article-title":"NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling","volume":"17","author":"Zhou","year":"2010","journal-title":"Cancer Cell"},{"key":"B144","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1146\/annurev-pathmechdis-012419-032847","article-title":"DAMPs, PAMPs, and LAMPs in immunity and sterile inflammation","volume":"15","author":"Zindel","year":"2020","journal-title":"Annu. Rev. Pathol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1078766\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T01:06:11Z","timestamp":1670202371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1078766\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":144,"alternative-id":["10.3389\/fphar.2022.1078766"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1078766","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"article-number":"1078766"}}